Last Price
16.83
Today's Change
-0.20 (1.17%)
Day's Change
16.59 - 17.02
Trading Volume
238,286
Profile
NEU
Exchange: Australian Securities Exchange Australian Securities Exchange
Currency: AUD AUD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Full Time Employees: 0 0
IPO Date: 2005-02-01 2005-02-01
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
Australia Faces Economic Pain From Trump Win, Treasurer Warns
2
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
